The NUB reimbursement pathway has been effective in bringing high-cost innovative medical technologies to the German market, but there are challenges. In MedTech Strategist, we assess the funding of medtech through NUBs and outlines the strengths and weaknesses of the NUB pathway.
Introduction to PDABs: How US states are addressing high-cost prescription drugs
An in-depth look at how PDABs function, their influence across different states, and the latest updates from Colorado, Maryland, Washington, and Oregon.